Skip to main content

Advertisement

SpringerLink
Log in

Renal-cell carcinoma in 2016

Advances in treatment — jostling for pole position

  • Year in Review
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

In 2016, two major trials provided conflicting evidence regarding the role of 1 year of adjuvant therapy with sunitinib for patients with high-risk renal-cell carcinoma. In the second-line metastatic setting, updated data from key trials showed that cabozantinib improved overall survival over everolimus, and nivolumab was associated with a better quality of life compared with everolimus. Finally, a phase II study in previously untreated patients showed cabozantinib to be superior to sunitinib.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1814–1823 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Motzer, R. J. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 16, 1473–1782 (2015).

    Article  CAS  PubMed  Google Scholar 

  4. Haas, N. B. et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387, 2008–2016 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ravaud, A. et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N. Engl. J. Med. 375, 2246–2254 (2016).

    Article  CAS  PubMed  Google Scholar 

  6. Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 17, 917–927 (2016).

    Article  CAS  PubMed  Google Scholar 

  7. Cella, D. et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol. 17, 994–1003 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Choueiri, T. K. et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2016.70.7398 (2016).

  9. Armstrong, A. J. et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 17, 378–388 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Tannir, N. M. et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur. Urol. 69, 866–874 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Motzer, R. J. et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 32, 2765–2772 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Bex, A. et al. Updated european association of urology guidelines regarding adjuvant therapy for renal cell carcinoma. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2016.11.034 (2016).

Download references

Author information

Authors and Affiliations

  1. Laurence Albiges is at the Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, 114 rue Edouard Vaillant, Villejuif, F-94805, France.,

    Laurence Albiges

  2. Toni K. Choueiri is at the Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana 1230, Boston, Massachusetts 02215, USA.,

    Toni K. Choueiri

Authors
  1. Laurence Albiges
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toni K. Choueiri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toni K. Choueiri.

Ethics declarations

Competing interests

L.A. declares that she is a consultant for and has an advisory role with Amgen, Bayer, Bristol-Myers Squibb, Cerulean, Novartis, Pfizer, and Sanofi, and receives research funding from Novartis and Pfizer. T.K.C. declares he is a consultant for and has an advisory role to Bayer, Bristol-Myers Squibb, Exelixis, GSK, Merck, Novartis, and Pfizer. He also receives research funding from AstraZeneca, Bristol-Myers Squibb, Exelixis, GSK, Merck, Novartis, Peloton, Pfizer, Roche, and Tracon.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Albiges, L., Choueiri, T. Advances in treatment — jostling for pole position. Nat Rev Clin Oncol 14, 82–84 (2017). https://doi.org/10.1038/nrclinonc.2016.224

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2016.224

  • Springer Nature Limited

This article is cited by

Search

Navigation